The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of ...
Scientists at Université de Montreal and its Institute for Research in Immunology and Cancer have begun a phase-1 clinical ...
AbCellera (ABCL) has pivoted to in-house drug development, with two Phase 1 assets and a recent share price surge despite ...
Warfighters must be healthy and at peak performance levels to execute their mission and remain lethal in battle. Effective ...
Dosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability ...
Expansion to three active C anadian sites marks a key milestone in advancing Trichomylin® softgel capsules into later-stage ...
President Donald Trump and Pfizer's CEO today announced "TrumpRX" and lower drug prices. But what does Pfizer sell? Here's ...
MET-097i’s mid-stage performance “bodes well” for Pfizer’s proposed buyout of Metsera, according to BMO Capital Markets, a ...
Companies are moving from using AI for distinct operations to applying the technology for control and optimization of the ...
The Chosun Ilbo on MSN
Korean, Chinese Firms Accelerate Obesity Drug Development
South Korean and Chinese pharmaceutical and biotech companies are accelerating the development of new obesity treatments to ...
Achieve Life Sciences (ACHV) is advancing cytisinicline, its sole product candidate, targeting FDA approval for nicotine ...
After years of heartbreak, researchers have found an experimental treatment that can slow the progression of Huntington’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback